207 related articles for article (PubMed ID: 26852128)
21. Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan.
Yamaguchi M; Suzuki R; Oguchi M; Asano N; Amaki J; Akiba T; Maeda T; Itasaka S; Kubota N; Saito Y; Kobayashi Y; Itami J; Ueda K; Miyazaki K; Ii N; Tomita N; Sekiguchi N; Takizawa J; Saito B; Murayama T; Ando T; Wada H; Hyo R; Ejima Y; Hasegawa M; Katayama N
J Clin Oncol; 2017 Jan; 35(1):32-39. PubMed ID: 28034070
[TBL] [Abstract][Full Text] [Related]
22. Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review.
Kim SJ; Yoon SE; Kim WS
J Hematol Oncol; 2018 Dec; 11(1):140. PubMed ID: 30567593
[TBL] [Abstract][Full Text] [Related]
23. Extranodal natural killer/T-cell lymphoma, nasal type: a Spanish multicentric retrospective survey.
Rozas-Muñoz E; Gallardo F; Pujol RM; Pérez-Ferriols A; Servitje O; Estrach T; Bastida J; Román C; Palacio-Aller L; Gil I; Martí RM; Vidal-Sarró D; García-Muret MP
Eur J Dermatol; 2018 Feb; 28(1):64-70. PubMed ID: 29400283
[TBL] [Abstract][Full Text] [Related]
24. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
Yamaguchi M; Tobinai K; Oguchi M; Ishizuka N; Kobayashi Y; Isobe Y; Ishizawa K; Maseki N; Itoh K; Usui N; Wasada I; Kinoshita T; Ohshima K; Matsuno Y; Terauchi T; Nawano S; Ishikura S; Kagami Y; Hotta T; Oshimi K
J Clin Oncol; 2009 Nov; 27(33):5594-600. PubMed ID: 19805668
[TBL] [Abstract][Full Text] [Related]
25. A comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages: The efficacy of CHOP regimen based concurrent chemoradiotherapy.
Cao J; Lan S; Shen L; Si H; Zhang N; Li H; Guo R
Oncotarget; 2017 Mar; 8(12):20362-20370. PubMed ID: 27901491
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcomes of upfront concurrent chemoradiotherapy followed by P-GDP regimen in newly diagnosed early stage extranodal nasal-type NK/T cell lymphoma: A prospective single-center phase II study.
Zhu F; Liu T; Pan H; Xiao Y; Li Q; Liu X; Chen W; Wu G; Zhang L
Medicine (Baltimore); 2020 Aug; 99(33):e21705. PubMed ID: 32872045
[TBL] [Abstract][Full Text] [Related]
27. Comparison of chemoradiotherapy with radiotherapy alone for early-stage extranodal natural killer/T-cell lymphoma, nasal type in elderly patients.
Su C; Nguyen KA; Bai HX; Balaji D; Cao Y; Karakousis G; Zhang PJ; Zhang G; Xiao R
Leuk Lymphoma; 2018 Jun; 59(6):1406-1412. PubMed ID: 28980517
[TBL] [Abstract][Full Text] [Related]
28. Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma.
Wang H; Li YX; Wang WH; Jin J; Dai JR; Wang SL; Liu YP; Song YW; Wang ZY; Liu QF; Fang H; Qi SN; Liu XF; Yu ZH
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1115-21. PubMed ID: 21514070
[TBL] [Abstract][Full Text] [Related]
29. Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase-based chemotherapy.
Li YY; Feng LL; Niu SQ; Wang HY; Zhang LL; Wang L; Xia ZJ; Huang HQ; Xia YF; Zhang YJ; Wang XC
Oncotarget; 2017 Feb; 8(7):11480-11488. PubMed ID: 28002792
[TBL] [Abstract][Full Text] [Related]
30. The Roles of Radiotherapy and Chemotherapy in the Era of Multimodal Treatment for Early-Stage Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma.
Kim TH; Kim JS; Suh YG; Cho J; Yang WI; Suh CO
Yonsei Med J; 2016 Jul; 57(4):846-54. PubMed ID: 27189276
[TBL] [Abstract][Full Text] [Related]
31. [Extranodal NK/T-cell lymphoma, nasal type: a clinical analysis].
Chen F; Shen CX; Wang HG; Li GX; Wang XQ; Wen Z
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Mar; 31(5):327-333. PubMed ID: 29871255
[No Abstract] [Full Text] [Related]
32. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.
Wang L; Wang ZH; Chen XQ; Li YJ; Wang KF; Xia YF; Xia ZJ
Cancer; 2013 Jan; 119(2):348-55. PubMed ID: 22811078
[TBL] [Abstract][Full Text] [Related]
33. Body mass index as a prognostic factor in patients with extranodal natural killer/T-cell lymphoma, nasal type.
Liu J; Deng YT; Zhang L; Li N; Jiang M; Zou LQ; Jiang Y
Oncotarget; 2016 Nov; 7(47):78159-78167. PubMed ID: 27556299
[TBL] [Abstract][Full Text] [Related]
34. Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma.
Tsai HJ; Lin SF; Chen CC; Chen TY; Su WC; Hwang WL; Lin JC; Chiou TJ; Kao WY; Chiu CF; Chang YF; Chang JS; Chang MC; Su IJ
Eur J Haematol; 2015 Feb; 94(2):130-7. PubMed ID: 24957163
[TBL] [Abstract][Full Text] [Related]
35. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type.
Yamaguchi M; Suzuki R; Oguchi M
Blood; 2018 Jun; 131(23):2528-2540. PubMed ID: 29602763
[TBL] [Abstract][Full Text] [Related]
36. Nasopharyngeal/nasal type NK/T lymphoma: analysis of 23 cases and current review of the literature.
Youssef YB; Bougmiza I; Bouabid Z; Achour B; Regaieg H; Sriha B; Belkadhi M; Omri HE; Khelif A
Kulak Burun Bogaz Ihtis Derg; 2012; 22(5):275-83. PubMed ID: 22991988
[TBL] [Abstract][Full Text] [Related]
37. Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma.
Huang Y; Jia B; Jiang S; Zhou S; Yang J; Liu P; Gui L; He X; Qin Y; Sun Y; Shi Y
J Hematol Oncol; 2017 Jan; 10(1):7. PubMed ID: 28057019
[TBL] [Abstract][Full Text] [Related]
38. Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma.
Yang CW; Wang CW; Hong RL; Tsai CL; Yao M; Tang JL; Lin CW; Cheng AL; Kuo SH
J Radiat Res; 2017 Jan; 58(1):114-122. PubMed ID: 27534792
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
Kim SJ; Kim K; Kim BS; Kim CY; Suh C; Huh J; Lee SW; Kim JS; Cho J; Lee GW; Kang KM; Eom HS; Pyo HR; Ahn YC; Ko YH; Kim WS
J Clin Oncol; 2009 Dec; 27(35):6027-32. PubMed ID: 19884539
[TBL] [Abstract][Full Text] [Related]
40. Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma.
Makita S; Tobinai K
Hematol Oncol Clin North Am; 2017 Apr; 31(2):239-253. PubMed ID: 28340876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
